Publications
Detailed Information
PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Min, Ahrum | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.date.accessioned | 2022-03-22T09:11:19Z | - |
dc.date.available | 2022-03-22T09:11:19Z | - |
dc.date.created | 2020-05-13 | - |
dc.date.created | 2020-05-13 | - |
dc.date.issued | 2020-02 | - |
dc.identifier.citation | Cancers, Vol.12 No.2, p. 394 | - |
dc.identifier.issn | 2072-6694 | - |
dc.identifier.other | 99534 | - |
dc.identifier.uri | https://hdl.handle.net/10371/177225 | - |
dc.description.abstract | Poly (ADP-ribose) polymerase (PARP) 1 is an essential molecule in DNA damage response by sensing DNA damage and docking DNA repair proteins on the damaged DNA site through a type of posttranslational modification, poly (ADP-Ribosyl)ation (PARylation). PARP inhibitors, which inhibit PARylation through competitively binding to NAD+ binding site of PARP1 and PARP2, have improved clinical benefits for BRCA mutated tumors, leading to their accelerated clinical application. However, the antitumor activities of PARP inhibitors in clinical development are different, due to PARP trapping activity beyond blocking PARylation reactions. In this review, we comprehensively address the current state of knowledge regarding the mechanisms of action of PARP inhibitors. We will also discuss the different effects of PARP inhibitors in combination with cytotoxic chemotherapeutic agents regarding the mechanism of regulating PARylation. | - |
dc.language | 영어 | - |
dc.publisher | Multidisciplinary Digital Publishing Institute (MDPI) | - |
dc.title | PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.3390/cancers12020394 | - |
dc.citation.journaltitle | Cancers | - |
dc.identifier.wosid | 000522477300140 | - |
dc.identifier.scopusid | 2-s2.0-85079116361 | - |
dc.citation.number | 2 | - |
dc.citation.startpage | 394 | - |
dc.citation.volume | 12 | - |
dc.identifier.sci | 000522477300140 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | POLY(ADP-RIBOSE) POLYMERASE 1 | - |
dc.subject.keywordPlus | TOPOISOMERASE-I INHIBITORS | - |
dc.subject.keywordPlus | PLATINUM-SENSITIVE OVARIAN | - |
dc.subject.keywordPlus | METASTATIC BREAST-CANCER | - |
dc.subject.keywordPlus | BASE EXCISION-REPAIR | - |
dc.subject.keywordPlus | DNA-DAMAGE RESPONSE | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | PHASE-I | - |
dc.subject.keywordPlus | MAINTENANCE THERAPY | - |
dc.subject.keywordPlus | SYNTHETIC LETHALITY | - |
dc.subject.keywordAuthor | PARP | - |
dc.subject.keywordAuthor | PARP inhibitors | - |
dc.subject.keywordAuthor | PARylation | - |
dc.subject.keywordAuthor | trapping | - |
dc.subject.keywordAuthor | cancer therapeutic strategy | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.